維生素K是活性凝血因子Ⅱ、Ⅶ、Ⅺ和Ⅹ形成所必需的物質(zhì)，缺乏維生素Ｋ會使凝血時間延長。美國ARYx Therapeutics公司在研新藥維生素K拮抗劑Tecarfarin作為新一代口服抗凝血劑，用于治療心房顫動、心臟瓣膜病和深靜脈血栓。已經(jīng)公布的Ⅱ和Ⅲ期臨床試驗數(shù)據(jù)顯示，Tecarfarin的療效與華法林具有可比性，并可能減少更多的藥物與食物或藥物之間的相互作用。目前該公司所做的臨床試驗已經(jīng)得到美國食品藥品監(jiān)督管理局（FDA）的書面確認。

Vitamin K is required to form the active clotting factors Ⅱ, Ⅶ, Ⅺ, and Ⅹ. Lacking of vitamin K could cause to extend blood coagulation time. The United States ARYx Therapeutics Company researched new drug, Tecarfarin that is one of vitamin K antagonists as a new generation of oral anticoagulant therapy and can be used in the treatment of atrial fibrillation (af), heart valve disease, and deep vein thrombosis. It is based on the published II and III phase of clinical trial to show that it has no less than Warfarin theropy result and may reduce the more medicine-food interactions. At present what the company does in clinical experiment has been received from the U.S. food and drug administration (FDA) written confirmation.

國家重大新藥創(chuàng)制專項（2011ZX09401-009；2010ZX09401-307-1-1）